M&A, R&D

Game change: Pfizer doubles down on its late-stage pipeline as CEO Read disavows a long reliance on M&A deals

For years, Pfizer CEO Ian Read stoutly insisted that a “transformative” merger with another major biopharma player was a completely viable way to achieve growth — even as industry insiders hooted about the R&D destruction that inevitably followed previous big league tie-ups.

For Pfizer {$PFE}, which never was burdened much with a rep for innovation in early-stage research, M&A was seen as perhaps its only shot at near-term growth — aside from the annual price hikes Read was sure to push through, until his showdown with President Donald Trump.

But now, in a big shift with large implications for M&A and the rest of the industry, Read is embracing the company’s late-stage pipeline as a near-term growth engine. And the CEO is stepping up his investment in R&D to position it alongside the biggest players on the planet, while staging a strategic retreat from M&A deals.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,100+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Director Process Development
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->